{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:12:55Z","timestamp":1787497975769,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s40263-018-0545-1","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T21:08:32Z","timestamp":1532034512000},"page":"689-696","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Nusinersen: A Review in 5q Spinal Muscular Atrophy"],"prefix":"10.1007","volume":"32","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,20]]},"reference":[{"issue":"4","key":"545_CR1","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nrneurol.2018.4","volume":"14","author":"EJN Groen","year":"2018","unstructured":"Groen EJN, Talbot K, Gillingwater TH. Advances in therapy for spinal muscular atrophy: promises and challenges. Nat Rev Neurol. 2018;14(4):214\u201324.","journal-title":"Nat Rev Neurol."},{"key":"545_CR2","unstructured":"US Library of Medicine. Genetics home reference: spinal muscular atrophy. 2018. \n                    http:\/\/ghr.nlm.nih.gov\/condition\/spinal-muscular-atrophy\n                    \n                  . Accessed 24 Apr 2018."},{"issue":"2","key":"545_CR3","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamapediatrics.2017.4409","volume":"172","author":"AM Burgart","year":"2018","unstructured":"Burgart AM, Magnus D, Tabor HK, et al. Ethical challenges confronted when providing nusinersen treatment for spinal muscular atrophy. JAMA Pediatr. 2018;172(2):188\u201392.","journal-title":"JAMA Pediatr."},{"key":"545_CR4","unstructured":"Biogen Idec Ltd. Spinraza 12\u00a0mg solution for injection: EU summary of product characteristics. 2018. \n                    http:\/\/www.ema.europa.eu\/ema\/\n                    \n                  . Accessed 27 Mar 2018."},{"key":"545_CR5","unstructured":"Biogen Inc. SPINRAZA (nusinersen) injection, for intrathecal use: US prescribing information. 2018. \n                    http:\/\/www.fda.gov\/\n                    \n                  . Accessed 11 Jun 2018."},{"issue":"4","key":"545_CR6","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","volume":"77","author":"SM Hoy","year":"2017","unstructured":"Hoy SM. Nusinersen: first global approval. Drugs. 2017;77(4):473\u20139.","journal-title":"Drugs."},{"issue":"10063","key":"545_CR7","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388(10063):3017\u201326.","journal-title":"Lancet"},{"issue":"8","key":"545_CR8","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/jcph.884","volume":"57","author":"KT Luu","year":"2017","unstructured":"Luu KT, Norris DA, Gunawan R, et al. Population pharmacokinetics of nusinersen in the cerebral spinal fluid and plasma of pediatric patients with spinal muscular atrophy following intrathecal administrations. J Clin Pharmacol. 2017;57(8):1031\u201341.","journal-title":"J Clin Pharmacol"},{"key":"545_CR9","unstructured":"European Medicines Agency. Nusinersen (Spinraza): EU assessment report. 2017. \n                    http:\/\/www.ema.europa.eu\/ema\/\n                    \n                  . Accessed 2 May 2018."},{"issue":"10","key":"545_CR10","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","volume":"86","author":"CA Chiriboga","year":"2016","unstructured":"Chiriboga CA, Swoboda KJ, Darras BT, et al. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology. 2016;86(10):890\u20137.","journal-title":"Neurology."},{"key":"545_CR11","unstructured":"US FDA Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceuticals review(s). 2016. \n                    http:\/\/www.fda.gov\/\n                    \n                  . Accessed 17 Apr 2018."},{"issue":"18","key":"545_CR12","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723\u201332.","journal-title":"N Engl J Med"},{"key":"545_CR13","unstructured":"Castro D, Farrar MA, Finkel R, et al. Longer-term assessment of the safety and efficacy of nusinersen for the treatment of infantile-onset spinal muscular atrophy (SMA): an interim analysis of the SHINE study. In: 2018 American Academy of Neurology Annual Meeting. 2018."},{"key":"545_CR14","unstructured":"Darras BT, Chiriboga CA, Montes J, et al. Nusinersen in treatment-na\u00efve patients with later-onset spinal muscular atrophy (SMA): efficacy results from a phase 1b\/2a multicentre study (CS2) and its open-label extension (CS12) [presentation]. In: 21st International Congress of the World Muscle Society. 2016."},{"issue":"7","key":"545_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625\u201335.","journal-title":"N Engl J Med"},{"issue":"2","key":"545_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3233\/JND-180315","volume":"5","author":"A Pechmann","year":"2018","unstructured":"Pechmann A, Langer T, Schorling D, et al. Evaluation of children with SMA type 1 under treatment with nusinersen within the expanded access program in Germany. J Neuromuscul Dis. 2018;5(2):135\u201343.","journal-title":"J Neuromuscul Dis."},{"issue":"Suppl 2","key":"545_CR17","doi-asserted-by":"publisher","first-page":"S211","DOI":"10.1016\/j.nmd.2017.06.423","volume":"27","author":"E Gargaun","year":"2017","unstructured":"Gargaun E, Aragon-Gawinska K, Seferian A, et al. First experience of nusinersen early access program in patients with spinal muscular atrophy type 1 [abstract no. P.383]. Neuromuscul Disord. 2017;27(Suppl 2):S211\u20132.","journal-title":"Neuromuscul Disord"},{"issue":"Suppl 1","key":"545_CR18","first-page":"A122","volume":"103","author":"M Scoto","year":"2017","unstructured":"Scoto M, Main M, Munot P, et al. Nusinersen (Spinraza) is the first drug approved for spinal muscular atrophy (SMA): initial experience in patients with SMA type 1 treated in the expanded access program (EAP) [abstract no. G299]. Arch Dis Child. 2017;103(Suppl 1):A122.","journal-title":"Arch Dis Child"},{"key":"545_CR19","doi-asserted-by":"crossref","unstructured":"Scoto M, Manzur A, Main M, et al. The use of nusinersen in the \u201creal world\u201d: the UK and Ireland experience with the expanded access program (EAP) [abstract no. MND03]. Neuromuscular Diorders. 2018;28(Suppl 1):S25.","DOI":"10.1016\/S0960-8966(18)30364-X"},{"issue":"Suppl 21","key":"545_CR20","first-page":"S265","volume":"82","author":"D Vivo De","year":"2017","unstructured":"De Vivo D, Bertini E, Hwu WL, et al. One-year outcomes following treatment with nusinersen: interim results from the NURTURE study of presymptomatic infants with genetically diagnosed spinal muscular atrophy (SMA) [abstract no. PL2-4]. Ann Neurol. 2017;82(Suppl 21):S265\u20136.","journal-title":"Ann Neurol"},{"key":"545_CR21","unstructured":"US National Institutes of Health. ClinicalTrials.gov. 2018. \n                    http:\/\/www.clinicaltrials.gov\/\n                    \n                  . Accessed 1 May 2018."},{"issue":"Suppl. 4","key":"545_CR22","first-page":"16","volume":"59","author":"E Mercuri","year":"2017","unstructured":"Mercuri E, Finkel RS, Farrar M, et al. Infants and children with spinal muscular atrophy (SMA) treated with nusinersen in clinical trials: an integrated safety analysis [abstract]. Dev Med Child Neurol. 2017;59(Suppl. 4):16\u20137.","journal-title":"Dev Med Child Neurol"},{"key":"545_CR23","unstructured":"Pharmaceuticals and Medical Devices Agency. Nusinersen: Japanese prescribing information. 2017. \n                    http:\/\/www.pmda.go.jp\/\n                    \n                  . Accessed 5 Jul 2018."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-018-0545-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0545-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0545-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T19:11:33Z","timestamp":1563563493000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-018-0545-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["545"],"URL":"https:\/\/doi.org\/10.1007\/s40263-018-0545-1","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"20 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sheridan Hoy is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}